Clinical Trial Detail

NCT ID NCT01449461
Title A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements yes
Sponsors Ariad Pharmaceuticals
Indications

Advanced Solid Tumor

diffuse large B-cell lymphoma

lung non-small cell carcinoma

anaplastic large cell lymphoma

Therapies

Brigatinib

Age Groups: senior adult

Additional content available in CKB BOOST